Cardio Diagnostics (NASDAQ:CDIO) PT Lowered to $1.35 at Benchmark

Cardio Diagnostics (NASDAQ:CDIO) had its target price dropped by equities research analysts at Benchmark from $4.00 to $1.35 in a report issued on Friday, Benzinga reports. The brokerage presently has a “speculative buy” rating on the stock. Benchmark’s price target would indicate a potential upside of 23.85% from the stock’s current price.

Cardio Diagnostics Stock Up 6.9 %

Cardio Diagnostics stock opened at $1.09 on Friday. Cardio Diagnostics has a 1-year low of $0.17 and a 1-year high of $3.56. The company has a fifty day simple moving average of $1.43 and a 200 day simple moving average of $1.51.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CDIO. Bank of America Corp DE bought a new position in shares of Cardio Diagnostics in the 1st quarter valued at about $59,000. Geode Capital Management LLC bought a new position in shares of Cardio Diagnostics in the 1st quarter valued at about $290,000. State Street Corp bought a new position in shares of Cardio Diagnostics in the 1st quarter valued at about $163,000. Vontobel Holding Ltd. bought a new position in shares of Cardio Diagnostics in the 4th quarter valued at about $30,000. Finally, Northern Trust Corp bought a new position in shares of Cardio Diagnostics in the 4th quarter valued at about $115,000. Institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.